Saltar al contenido
Merck

Deriving Schwann cells from hPSCs enables disease modeling and drug discovery for diabetic peripheral neuropathy.

Cell stem cell (2023-05-06)
Homa Majd, Sadaf Amin, Zaniar Ghazizadeh, Andrius Cesiulis, Edgardo Arroyo, Karen Lankford, Alireza Majd, Sina Farahvashi, Angeline K Chemel, Mesomachukwu Okoye, Megan D Scantlen, Jason Tchieu, Elizabeth L Calder, Valerie Le Rouzic, Bradley Shibata, Abolfazl Arab, Hani Goodarzi, Gavril Pasternak, Jeffery D Kocsis, Shuibing Chen, Lorenz Studer, Faranak Fattahi
RESUMEN

Schwann cells (SCs) are the primary glia of the peripheral nervous system. SCs are involved in many debilitating disorders, including diabetic peripheral neuropathy (DPN). Here, we present a strategy for deriving SCs from human pluripotent stem cells (hPSCs) that enables comprehensive studies of SC development, physiology, and disease. hPSC-derived SCs recapitulate the molecular features of primary SCs and are capable of in vitro and in vivo myelination. We established a model of DPN that revealed the selective vulnerability of SCs to high glucose. We performed a high-throughput screen and found that an antidepressant drug, bupropion, counteracts glucotoxicity in SCs. Treatment of hyperglycemic mice with bupropion prevents their sensory dysfunction, SC death, and myelin damage. Further, our retrospective analysis of health records revealed that bupropion treatment is associated with a lower incidence of neuropathy among diabetic patients. These results highlight the power of this approach for identifying therapeutic candidates for DPN.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Monofosfato de N6,2′-O-dibutiriladenosina 3′,5′-cíclico sodium salt, ≥96% (HPLC), powder
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Número de referencia del producto (SKU)Tamaño de envaseDisponibilidadPrecioCantidad
500 mg
Fecha estimada de envío 23 de marzo de 2025
USD 385.00
Sigma-Aldrich
Monofosfato de N6,2′-O-dibutiriladenosina 3′,5′-cíclico sodium salt, ≥97% (HPLC), powder
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Número de referencia del producto (SKU)Tamaño de envaseDisponibilidadPrecioCantidad
500 mg
Fecha estimada de envío 23 de marzo de 2025
USD 385.00